



SHL/SEC/2018

August 16, 2018

**Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.**

Company Code: **537253**

**Sub.: INVESTOR RELEASE-SUNIL HEALTHCARE LTD. FINANCIAL
PERFORMANCE IN Q1- FY19**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, please find attached Investor release on financial performance of the Company for the first quarter ended June 30, 2018 of the financial year 2018-19.

We hope you will find the same in order, and take the information in your record.

Thanking you,

Yours sincerely,
for **SUNIL HEALTHCARE LIMITED**

A handwritten signature in blue ink, appearing to read "Santosh Kumar Sharma".

**SANTOSH KUMAR SHARMA
COMPANY SECRETARY & COMPLIANCE OFFICER**

Encl : As above

**CC: Calcutta Stock Exchange Limited
7, Lyons Range
Kolkata- 700 001.**

Sunil Healthcare Limited

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049

T: +91 11 49435555/00 F: +91 11 43850087 E-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com

CIN No.: L24302DL1973PLC189662

Investor Release

Sunil Healthcare Ltd. Financial Performance in Q1FY19

August 14, 2018, New Delhi - Sunil Healthcare Ltd, a leading manufacturer of Empty Hard Gelatin Capsules, has announced its Unaudited Financial Results for the Quarter ended 30th June 2018.

Key Standalone Financial Highlights are as follows:

Rs. In Millions	Q1FY19	Q1FY18
Net Revenue	201.30	203.43
EBITDA	35.00	42.72
EBITDA Margin	17.4%	21.0%
Profit Before Tax	6.54	19.04
PBT Margin	3.2%	9.4%
PAT	4.74	12.60
PAT Margin	2.4%	6.2%
Cash PAT	19.16	24.08
Cash PAT Margin	9.5%	11.8%

Commenting on the Standalone Results, Mr. D. Gnanasekaran (CEO) said, “This Fiscal has begun on a challenging note with continued pricing pressure being faced by the Industry. Our performance, though good relative to the state of the Industry, has been impacted due to external factors as enlisted below:

1. Sustained pricing pressure on our finished product due to adverse market conditions and reduced filling of shells due to unavailability of certain key APIs formulated in hard capsules
2. As per Ind-AS exchange fluctuations in foreign currency loans booked into P&L which was pre Ind-As, impacted in to the balance useful life of the fixed asset.
3. Mark to Market exchange losses recognized on forward contracts as a result of currency depreciation during the quarter

Despite the above, we have continued to maintain our performance metric in these challenging times and remain ahead of the industry in terms of performance and execution. Noteworthy points are as follows:

1. We continue to maintain high utilization levels including the new capacity which came on stream in Q4 of last fiscal year
2. Our market share continues to increase despite the difficult Industry scenario. We strongly believe that we are well positioned to take the advantage when the cycle turns

Road Ahead for Us:

The focus of the Company will remain at maximizing utilization rates and driving down costs to further improve the efficiencies and maintain industry leading margins.

We will continue to endeavor to optimize our product mix and geographical mix to improve the realizations to the maximum extent possible.

We anticipate some volatility in our raw material prices in the coming quarters since a few of the larger suppliers are not operating at full capacities due to varied reasons. The quantum of its impact is not yet known, but we are working to minimize the same.

We remain committed to continue to put our best foot forward to navigate through these challenging times in the best possible manner.

About Sunil Healthcare Ltd

Sunil Healthcare Ltd, is the second largest manufacturer of Empty Hard Gelatin Capsules in India. A GoI recognized Star Export House, ~50% of revenues are from exports. With four decades of experience, and a strong brand equity “Sunloc”, the company is a preferred vendor for large pharmaceutical companies.

The company was the pioneer of Double lock and Triple lock technology in India. With a strong focus on R &D, the company is constantly innovating its product line to cater to the industry requirements. For more information, please visit the company website www.sunilhealthcare.com

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company:	Investor Relations Advisors:
Sunil Healthcare Limited CIN: L24302DL1973PLC189662	Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285
Mr. Pawan Rathi, Chief Financial Officer Email: cfo@sunilhealthcare.com	Mr. Shogun Jain / Mr. Pratik Shah Contact Numbers: +91 77383 77756 / +91 97692 60769 Email: shogun.jain@sgapl.net / pratik.shah@sgapl.net